Streamlining management in TAVI. The Benchmark Registry. #TAVR #PCRLV Best practices:

Coronary Access after TAVI Multi-modality teaching using: ⚙️ SIM 🫀 Real valves, 🐷 Real hearts, 📺 Smart screen and Smart people 🤓 Marco Barbanti Alessandro Beneduce @martinandreas Education. Revolution. #PCRLV23

The end of #PCRLV 2023! Quote of the conference from Dr. Michael J. Reardon concerning #TAVR deployment: "We pace at 140, 180 makes you feel like you're dying...140... makes you feel like you're in love..."

Opening and Welcome to #NYValves2024 ✅ new iCoach sessions integrating imaging and intervention ✅ dedicated surgical track ✅ late-breaking trials Excited!!

TMVR in heavily calcified MAC case. Incredible result! Congratulations to the Oregon Team. ☑️ controlled, co-axial deployment ☑️ well-sized, no significant stenosis ☑️ no significant LVOTO #NYValves2024

Innovalve TWIST device represents an advancement in #TMVR, by capturing the chordae, preserving LV geometry and reducing risk of LVOTO. Great session and presentstion! Chet Nichols III

Day 2 #NYValves2024: Incredible Hands-on training on transeptal puncture and mitral TEER using both Abbott Mitraclip and Edwards Lifesciences Pascal devices. Image guidance with live TEE simulation and examples of ICE. Cardiovascular Research Foundation

More Hands-on training this time with leaders Jaffar Khan and Adam Greenbaum . Pearls of wisdom on how to navigate the challenges of coronary access post-TAVR and nuances of Valve-in-valve procedures. #NYValve2024 Cardiovascular Research Foundation

Day 3 @ #NYValves2024 Cardiovascular Research Foundation Summary of ALIGN-AR: ✅ met 30-day safety and 1-year efficacy targets ✅ improved symptom/functional status ✅ good haemynamic results BUT: ❎ 24% Pacemaker implantation ❎ 2.2% operative mortality (1.1% for SAVR)

EXPANDed Study: Evaluating moderate vs severe SMR which lie on a spectrum⋮ 🔹Similarity in EF/volumes at baseline 🔹Reduction in LV volumes 🔹Improvement in NYHA functional status 🔹Improvement in QOL 🔹Reduction in heart failure hospitalisation #NYValves2024 Cardiovascular Research Foundation

TEER vs TMVR Retrospective using PRIME-MR/CHOICE-MI registry data. Red-zone Anatomy > unsuitable for TEER #NYValves2024 Cardiovascular Research Foundation

Pacemakers in TAVR from PARTNER 2 registry: ➡️ 12.5% PPM rate @ 30d in balloon-expandable TAVR patients ➡️ PPM implantation does not impact mortality @ 5 years ➡️ Risk factors for PPM - valve size, oversizing and implant depth. jacc.org/doi/10.1016/j.… JACC Journals

doi.org/10.1093/eurhea… Important epidemiological data. - Essentially stable prevalence of severe #AorticStenosis - More valve replacement is occurring BUT: - AS remains majorly undertreated (40%) in the cohort ?explained by some data collection being pre-#TAVR era